The same question that applies to GHK-Cu applies here, and is if anything more important for AHK-Cu because fewer products bother to answer it. A stated concentration of 1%, or equivalently 10mg/mL, allows the buyer to evaluate the product against what the research literature has actually used. A product that lists AHK-Cu without stating how much is present cannot be assessed against anything.

The stock solution caveat applies here too. AHK-Cu is available to formulators as pure powder and as pre-dissolved stock solutions of varying concentrations. A "1% AHK-Cu" claim that refers to 1% of a stock solution rather than 1% pure Copper Tripeptide-3 by weight represents a substantially lower actual active concentration. The most unambiguous disclosure combines a percentage and a mg/mL figure: both referring to the same concentration of pure active, and together leaving no room for interpretation.

This criterion is specific to AHK-Cu and catches a number of buyers off guard. AHK-Cu does not appear on an INCI list as "AHK-Cu." Its correct INCI name is Copper Tripeptide-3. GHK-Cu is Copper Tripeptide-1. A buyer who searches an ingredients list for "AHK-Cu" and does not find it may incorrectly conclude the product does not contain it, or may be misled by a product that uses the shorthand "AHK-Cu" in its marketing without ensuring the INCI list is easy to cross-reference.

Once you know to look for Copper Tripeptide-3, INCI position becomes the next diagnostic. Ingredients are listed in descending order of concentration above 1%. Below 1%, any order is permitted. If Copper Tripeptide-3 appears near the bottom of a long list, the concentration is likely below 1% and potentially substantially lower. In a properly formulated 1% AHK-Cu serum in a typical aqueous base, Copper Tripeptide-3 should appear after water and the primary humectants, and before the preservative system. For more on reading INCI order, see what most copper peptide labels don't tell you.

AHK-Cu appears in the UK market primarily in two forms: as a standalone serum where it is the primary active, and as one ingredient among several in a multi-active hair serum alongside compounds like biotin, caffeine, saw palmetto, or other peptides. The distinction matters for the same reason it matters with GHK-Cu: in a multi-active product, the AHK-Cu concentration may be substantially lower than any headline figure suggests, and without individual concentration disclosure the buyer cannot know what they are actually getting.

A multi-active hair serum is not an inferior product: it is a different proposition, targeting multiple pathways at lower individual concentrations. But a product that does not disclose the individual concentration of AHK-Cu cannot be evaluated against the hair follicle research that uses Copper Tripeptide-3 as a standalone active at a defined concentration. For a detailed side-by-side of AHK-Cu and GHK-Cu specifically, see GHK-Cu vs AHK-Cu: Which Copper Peptide Is Right for You?

AHK-Cu is a scalp-targeted compound. The majority of people using it are doing so as part of a hair loss protocol, and a meaningful proportion of those protocols include scalp microneedling. This makes the carrier formulation more relevant for AHK-Cu than for a compound used primarily on intact facial skin.

Glycol solvents (propylene glycol, propanediol, pentylene glycol) are commonly used in cosmetic carriers. They are broadly considered safe on intact skin but are commonly avoided in microneedling protocols, where the temporary micro-channels created during needling increase dermal absorption of everything in the formula. A glycol-free aqueous carrier built on glycerin and hyaluronic acid is the simpler option for users prioritising microneedling compatibility.

It is worth noting that glycol-free scalp serums are less common in the market than glycol-containing ones. Glycols serve a legitimate solubility function for some actives and reduce manufacturing complexity. A glycol-free formulation requires a carrier built to work without them, which is a deliberate formulation decision rather than a default.

AHK-Cu as a finished serum is significantly harder to source in the UK than GHK-Cu. The majority of standalone AHK-Cu serums are formulated and sold by US brands. Some are listed on UK marketplaces but ship from the US, with the associated import costs, customs uncertainty, and delivery unpredictability that creates for a product used daily.

UK cosmetic products must be registered on the UK Cosmetic Products Notification Portal (SCPN) before they can be placed on the UK market. This requires a Product Information File including a safety assessment. Products imported informally or sold through grey channels frequently lack this registration, which means no documented safety assessment exists for their UK sale.

A UK-formulated product registered on the SCPN has a traceable regulatory standing. It also ships domestically, restocks reliably, and does not carry the import friction that makes US-sourced products inconvenient as a daily-use item.

Products meeting all five criteria are uncommon in the UK AHK-Cu market, which is smaller and less transparent than the broader copper peptide market.

Against the five criteria: concentration stated explicitly at 1% (10mg/mL); Copper Tripeptide-3 appears third in the INCI list, after water and glycerin, before hyaluronic acid and the preservative system; it is a standalone serum with a single primary active; the carrier is glycol-free; and it is UK-formulated and SCPN registered.

For the full research background on what AHK-Cu is and what the literature supports, see the AHK-Cu article in the Research and Notes section.

AmpleLab products are cosmetic formulations registered on the UK Cosmetic Products Notification Portal. They are not medicines and are not intended to diagnose, treat, cure, or prevent any disease or medical condition. Research references are provided for informational purposes and do not constitute clinical claims.

AmpleLab.